{"id":"mineralocorticoid-receptor-antagonist-potassium-canrenoate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Menstrual irregularities"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a mineralocorticoid receptor antagonist, potassium-canrenoate inhibits the binding of aldosterone to its receptor in the collecting duct of the nephron. This prevents sodium reabsorption and potassium wasting, leading to increased sodium and water excretion while conserving potassium. The drug is used primarily in conditions characterized by aldosterone excess or where aldosterone antagonism provides therapeutic benefit, such as heart failure and hypertension.","oneSentence":"Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:27.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure"},{"name":"Hypertension"},{"name":"Primary aldosteronism"}]},"trialDetails":[{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT04912011","phase":"PHASE4","title":"Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.","status":"UNKNOWN","sponsor":"Pomeranian Medical University Szczecin","startDate":"2021-01-01","conditions":"COVID-19 Pneumonia","enrollment":50},{"nctId":"NCT02585843","phase":"PHASE2, PHASE3","title":"Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-11","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT01882179","phase":"PHASE3","title":"Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-11","conditions":"ST-elevation Myocardial Infarction","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mineralocorticoid receptor antagonist potassium-canrenoate","genericName":"Mineralocorticoid receptor antagonist potassium-canrenoate","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Potassium-canrenoate blocks mineralocorticoid receptors to reduce sodium reabsorption and potassium excretion in the kidney, lowering blood pressure and reducing fluid retention. Used for Heart failure, Hypertension, Primary aldosteronism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}